Chemotherapy-induced peripheral neuropathy (CIPN) is a major, dose-limiting adverse effect experienced by cancer patients. Advancements in mechanism-based risk mitigation and effective treatments for CIPN can be aided by suitable in vitro assays. To this end, we developed a multiparametric morphology-centered rat dorsal root ganglion (DRG) assay. Morphologic alterations in subcellular structures of neurons and non-neurons were analyzed with an automated microscopy system. Stains for NeuN (a neuron-specific nuclear protein) and Tuj-1 (b-III tubulin) were used to identify neuronal cell nuclei and neuronal cell bodies/neurites, respectively. Vimentin staining (a component of Schwann cell intermediate filaments) was used to label non-neuronal supporting cells. Nuclei that stained with DAPI, but lacked NeuN represented non-neuronal cells. Images were analyzed following 24 h of continuous exposure to CIPN-inducing agents and 72 h after drug removal to provide a dynamic measure of recovery from initial drug effects. Treatment with bortezomib, cisplatin, eribulin, paclitaxel or vincristine induced a dose-dependent loss of neurite/process areas, mimicking the 'dying back' degeneration of axons, a histopathological hallmark of clinical CIPN in vivo. The IC 50 for neurite loss was within 3-fold of the maximal clinical exposure (Cmax) for all five CIPN-inducing drugs, but was >4-or ! 28-fold of the Cmax for 2 non-CIPN-inducing agents. Compound-specific effects, eg, neurite fragmentation by cisplatin or bortezomib and enlarged neuronal cell bodies by paclitaxel, were also observed. Collectively, these results support the use of a quantitative, morphologic evaluation and a DRG cell culture model to inform risk and examine mechanisms of CIPN.
multiple mechanistic hypotheses that seek to explain the pathogenesis of CIPN. Notably, histomorphologic changes observed during CIPN are fairly consistent (Han and Smith, 2013) .
Although in vivo models have informed much of what we currently know about CIPN, the labor intensive nature of these studies and routine use of animal models limits application for mechanistic investigations or screening in early stages of drug discovery (Carozzi et al., 2010; Hoke and Ray, 2014; Leandri et al., 2012) . Several neuronal cell culture models have been established to assess neurotoxicity associated with chemicals or chemotherapeutics including CIPN agents Wheeler et al., 2015) . These in vitro models provide meaningful information about the general neurotoxicity, but fail to recapitulate the histopathology of CIPN observed in vivo. These models have typically employed a single neuronal cell type of non-peripheral nerve origin, such as human neural progenitor cells, human induced pluripotent stem cell (iPSC) derived central nervous system neurons, human embryonic stem cell-derived hN2TM cells or several neuronal cell lines (PC-12; SH-SY5Y) Radio et al., 2008; Sirenko et al., 2014; Wheeler et al., 2015) . In these investigations, the broad cytotoxicity with or without morphologic endpoints has been evaluated.
Use of a single neuronal cell-type in culture is not reflective of DRGs in situ. CIPN is predominately a sensory axonopathy and neuronopathy and the sensory neurons residing in DRGs are the primary target (Argyriou et al., 2014; Hershman et al., 2014; Miltenburg and Boogerd, 2014) . Histologically, dorsal root ganglia (DRG) contain both sensory neurons and non-neuronal supporting cells (Bunge et al., 1967) . An in vitro model of CIPN useful in mechanistic or other discovery strategies should therefore recapitulate the histopathological features of CIPN and it should retain a multicellular phenotype as is true in vivo (Delree et al., 1989; Grothe and Unsicker, 1987; Li et al., 1996; Wrathall et al., 1981) . In previous studies, cultures of DRGs or DRG explants have been used to characterize CIPN (Malgrange et al., 1994; Scuteri et al., 2006; Yang et al., 2009) . Notably, these studies did not report or evaluate drug effects on non-neuronal components in the DRG cultures. Furthermore, inhibition of regeneration (outgrowth of new neurites) rather than degeneration of existing neurites (axonopathy) or neuronal bodies (neuronopathy) was the endpoint measured. A multiparametric morphology-based model of CIPN can contribute to the evaluation and elucidation of mechanisms and discovery of potential treatments for CIPN.
In the studies presented herein, we employed quantitative morphologic analysis of rat-derived DRG cultures to establish the histopathological changes that characterize CIPN in vitro. We found that CIPN-inducing drugs (bortezomib, cisplatin, eribulin, paclitaxel and vincristine) shared several common morphologic features in that (1) the morphologic changes observed reproduced the 'dying back' degeneration of axons; (2) they caused a differential loss of neurites; (3) they induced a significant loss of neurites or non-neuronal processes at concentrations <3Â the peak plasma concentrations observed clinically (Cmax). In contrast, drugs that have not been shown to cause CIPN, gefitinib and hydroxyurea, were without any statistically significant effects at concentrations ! 28 or > 4-fold of the Cmax, respectively. Importantly, drug-specific changes in subcellular morphology of DRG neuronal cell bodies and neurites were observed. These results demonstrate the ability of a primary rat DRG multicellular culture model to reproduce the histopathological features of CIPN and that it can support in vitro investigations of CIPN.
MATERIALS AND METHODS

Cell Culture
Cryopreserved rat dorsal root ganglion cells (Lonza, Walkersville, MD, R-DRG-505) were thawed, plated, and maintained per manufacturer's instructions (http://bio.lonza.com/up loads/ tx_mwaxmarketingmaterial/Lonza_ManualsProductInstr uctions_Instructions_-_Rat_Neonatal _DRG_Neuronal_Cell_ System.pdf). In brief, DRG cells were thawed, passed through a 60-lm Cell Strainer (PluriSelect, San Diego, CA) and plated in fully supplemented Primary Neuron Basal Medium (Lonza) using poly-D-lysine coated Greiner 384-well plates at a target density of 4000 cells in 100 ll medium per well. The fully supplemented medium contained 2 mM L-glutamine, 50 mg/ml Gentamicin, 37 ng/ml Amphotericin, and 2% NSF-1. After 4 h, 75% of the medium was removed and fresh, pre-warmed medium containing mitotic inhibitors (17.5 lg/ml 1-b-D-ribofuranosyluracil, and 7.5 lg/ml of 5-fluoro-2-deoxyuridine; Sigma, St. Louis MO) was added. Medium change was performed on Days 1, 4 and 5 as indicated in Figure 1 . Cell cultures were incubated at 37 C and 5% CO 2 .
Drug Treatment
All drugs were obtained from the NCI Developmental Therapeutics Program repository (Rockville, MD), and tested at multiple concentrations in a range that bracketed the maximal clinical peak plasma concentration (Cmax) of each drug: Eribulin (NSC 707389), 0.01-1 lM; Paclitaxel (NSC 125973), 0.1-30 lM; Bortezomib (NSC 681239) 0.01-1 lM; Vincristine (NSC 67574), 0.001-0.1 lM; Cisplatin (NSC 119875), 0.3-100 lM; Hydroxyurea (NSC 32065), 1-300 lM; Gefitinib (NSC 715055), 0.1-10 lM and Thalidomide (NSC 66847), 3-300 lM. The stock solution of all drugs was prepared in DMSO at 300-or 1000-fold the testing concentrations. Equal volumes of DMSO were used for all treatments and one set of time-matched vehicle controls were included on each plate. Final concentration of DMSO did not exceed 0.3% DMSO. As shown in Figure 1 , on Day 4, medium was replaced with mitotic inhibitor-free medium, and drugs were added to culture medium using a HP D300 digital dispenser (Tecan Mannedorf, Switzerland). Cells were exposed to drugs at 5 or 6 concentrations at half-log intervals in triplicate wells/concentration for 24 h. A duplicate plate was washed 3 times with PBS for 5 min per wash to remove drug, and fresh mitotic inhibitor-free medium was added for an additional 72 h. For all drugs, three to six independent replicate experiments were conducted using independent lots of cryopreserved DRG cells.
Antibody, Isotype and Peptide
Primary antibodies tested for immunostaining were: anti-Tuj-1 (Neuromics, MO15013) 1:1000 
Capillary Electrophoresis Immunoassay
The expression of target proteins was determined by the capillary electrophoresis immunoassay using the Wes TM size-based
Simple Western system (ProteinSimple, San Jose, CA) as described previously (Guo et al., 2015) . In brief, DRG cells were cultured in 384-or 24-well plates and the whole cell lysates from untreated wells were collected on Day 5 and Day 8, corresponding to the 24-h exposure and 72-h post-wash (Figure 1 ), using RIPA buffer (EMD Millipore) containing 0.5% SDS (Sigma), 1Â Halt Protease Inhibitor Cocktail (Thermo Scientific), 1Â Phosphatase Inhibitor Cocktail (Sigma) and 1Â Protease Inhibitor Cocktail (Sigma). Collection of nuclear and cytoplasmic fractions was carried out using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). The lysate protein concentration was determined using the Pierce BCA protein assay kit (Thermo Scientific) and the Infinite V R M1000 plate reader (TECAN). For the Simple Western analysis, DRG lysates were mixed with reagents in the master kit of respective molecular weight ranges (ProteinSimple) and loaded at 80 or 160 pg in each capillary. The primary antibodies were diluted with antibody diluent (ProteinSimple) at 1:50 for Tuj-1 (Neuromics, MO15013) and SOX2 (Abcam, ab137385), 1:1000 for vimentin (Abcam, ab8069), 1:25 for glutamine synthetase (EMD Millipore, MAB302).
Immunocytochemical Staining and Imaging
Cells were fixed and permeabilized in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl 2 , pH ¼ 6.9) containing 8% paraformaldehyde (EMS, Fort Washington, PA), 0.3% Glutaraldehyde (Sigma) and 1% Triton X-100 (Sigma) for 5 min. Plates were then washed 3 times with PBS for 5 min and either stained immediately or stored at 2-8 C until staining was able to proceed. Cells were pretreated with Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE, 927-40000) and incubated with primary antibodies against Tuj-1, NeuN, and vimentin in blocking buffer for 2 h at 37 C. Nuclei were stained with DAPI (Sigma, D9564) for 7-10 min and then washed with PBS. Stained cells were imaged in 4 different preset channels using the IN Cell Analyzer 2000 (General Electric, Piscataway, NJ): DAPI (nuclei), FITC (NeuN), Cy3 (Tuj-1), and Cy5 (Vimentin). Nine or four fields per well were imaged with a 20Â or 10Â high numerical aperture objective, respectively. Images of the control wells were used to calibrate exposure times for the entire plate.
High Content Image Analysis
Images were analyzed using IN Cell Analyzer Workstation 3.71 software; specifically, the Multi-Target Analysis module was used for segmentation of target structures (Kim et al., 2011) . The background signal level was determined by the measurement of cells stained with the respective isotype IgG at a protein concentration identical to the primary antibody. Channels for NeuN and Tuj-1 were used for analysis of neuronal cells. The top-hat method with a minimal area of 120 or 200 mm 2 was used to segment the nuclei and cell bodies of neuronal cells, respectively. Multiscale top-hat segmentation method was utilized for neurite analysis. Channels for DAPI and vimentin were used to analyze non-neuronal cells. Top-hat with a minimal area of 30 mm 2 was used to segment nuclei while cell body area was evaluated using collar segmentation with a radius of 2 mm. The nonneuronal cell processes were segmented by the multiscale tophat method. All protocol parameters were established by visual confirmation that the intended target was correctly segmented, with consistent accuracy across plates and replicate experiments. Minor changes to the algorithm, ie, sensitivity adjustments or filtering-out incorrectly segmented objects based on the size or signal intensity of stains, were made on a plate-byplate basis to account for differences in staining intensities.
Data Analysis and Statistics
Drug effects were measured immediately following 24 h of continuous exposure (24-h exposure) and 72-h post-drug removal. At each time point, cell counts and total area of cell processes of neuronal or non-neuronal cells were quantified using markers for NeuN, Tuj-1 and vimentin with a DAPI nuclear stain. The nuclear cell count was used to assess overt cytotoxicity, and the total area of neurites or non-neuronal cell processes was used to evaluate neurite/process specific effects. Sizes of neuronal and non-neuronal cell bodies were measured as indicated.
Fragments of cell processes were counted. Data were expressed as mean 6 standard deviation (SD) or standard error of the mean (SEM). Concentration-dependent decreases in cell counts and the total area of neurites or processes were calculated as a fraction of the time-matched vehicle (0.1% or 0.3% DMSO) control group and fitted with the Hill equation using GraphPad Prism 6 (GraphPad Software, Inc. La Jolla, CA). Multiple cross- comparisons of drug-induced changes on the total area of processes and cell counts of neuronal and non-neuronal cells were analyzed by the 2-way analysis of variance (ANOVA) followed by Sidak's multiple comparisons test using GraphPad Prism 6. A P value < .05 was considered statistically significant.
RESULTS
Characterization and Optimization of DRG Culture System
Since primary rat DRG cultures consist of a heterogeneous population of cells that includes terminally differentiated sensory neuronal cells (neurons) and proliferative supporting cells and/ or non-neuronal cells (mainly Schwann cells) (Delree et al., 1989; Grothe and Unsicker, 1987; Li et al., 1996; Wrathall et al., 1981) , we characterized the cells in the culture and explored biomarkers that could identify neuronal and non-neuronal cells.
Among the biomarkers tested, we found NeuN to be expressed exclusively in neuronal cell nuclei. As expected, DAPI stained the nuclei of all cells. In terms of target specificity and signal intensity, Tuj-1was superior to peripherin and neurofilament antibodies (data not shown) in staining neuronal cell bodies and neurites. Vimentin was a superior biomarker compared with S100, GFAP, acetylated a-tubulin and total a-tubulin in its ability to specifically stain cell bodies and projections (processes) of non-neuronal cells. Therefore, antibodies against NeuN, Tuj-1 and vimentin, along with DAPI, were used in the assay to distinguish neuronal and non-neuronal cells.
A high expression level of Tuj-1 and vimentin in DRG cell cultures was demonstrated by imaging and analysis of the whole cell lysates with the capillary electrophoresis immunoassay. Tuj-1 and vimentin were detected by a clear band at 55 and 58 kDa, respectively, with an expression level of 2-or 3-fold over that of the loading control protein GAPDH ( Figs. 2A and B) . A 4-color/channel merged image of DRG cells after 5 days in culture is shown in Figure 2C . There are four neuronal cells in the field; each of them has a single, round nucleus stained positive for NeuN (in white) and residing in a large (10-20 lm in diameter), round cell body stained positive for Tuj-1 (in red). It appears that several neurites that stain positive for Tuj-1 sprout off from each neuronal cell body and extend away from surrounding areas in all directions, forming networks with neurites of other neurons along the path of progression. The non-neuronal cells all stained positive for vimentin (in green) and most of them exhibit characteristic morphologic features of Schwann cells in culture (Li et al., 1996; Wrathall et al., 1981) , with a single, small (< 10 lm in length), spindle-shaped nucleus (DAPI). There is little cytoplasm around the nucleus of these cells (a small ratio of cytosol/nucleus) and the cell bodies are bipolar with long, thin projections or processes extending from each side of the cell body. These long processes either form a dense bundle with neurites or travel away from the cell body side-by-side, with a single thread of neurites.
Two types of non-neuronal cells with morphology distinct from Schwann cells were also observed in the cultures; these cells were vimentin-positive, Tuj-1-negative, and had either a small, round, flat cell body or a large flat cell body with multipolar wide projections that were not associated with any neurites. For additional characterization of non-neuronal cells, glial specific protein expression and optimal culture conditions were evaluated. DRG lysates of either the whole cell or subcellular fractions was analyzed by capillary electrophoresis. Among several glial cell specific proteins probed, only SOX2 and GS had detectable expression. Results from these analyses are presented in Supplementary materials and Supplementary Figures 1-4 .
Optimal plating density of DRG cells was determined prior to drug testing. A plating density targeting 4000 cells per well using a 384-well plate and culturing for 5 days prior to treatment was determined to be optimal (Supplementary Figure 5) . DMSO at concentrations of either 0.1% or 0.3% did not have effects on either the cell count or the area of neurites or neuronal processes (Supplementary Figure 6) .
Differential Quantification of Cellular Morphology Using Automated Image Analysis
A target specific algorithm for rapid processing of cellular morphology was a critical feature of a morphology-centered in vitro assay. Figure 3 shows the image from Figure 2C , merged for 2 wavelengths (NeuN and Tuj-1 channels in Figure 3A ; DAPI and vimentin channels in Figure 3B ) to illustrate the neuronal and non-neuronal components. The merged images allowed differential quantification of DRG neuronal and non-neuronal nuclei and processes. Segmentation of nuclei and processes by the IN Cell Analyzer is marked with a thin line in blue, green or yellow surrounding the identified target structures in Figures 3C and D Figure 7) .
Quantification of Drug Effects on Cultured DRG Cells
A summary of drug effects quantified by IC 50 values is provided in Table 1 . Figures 4-9 show representative images and/or doseresponse curves for each of the individual agents on neuronal and non-neuronal cells, and effects are distinguished between cell bodies and cell neurites or processes. In each figure, images of time-matched controls are shown in panels A and E, drug treatments are shown in panels B and F.
Vincristine Figure 4 shows the responses of the DRG cells to vincristine. At 24-h exposure (Figs. 4C and D) , vincristine showed no effects on neuronal cell counts. In contrast, vincristine caused statistically significant dose-dependent decreases in non-neuronal cell counts with an IC 50 of 0.088 lM. Notably, vincristine also caused a dose-dependent reduction in both neurite and non-neuronal process areas (IC 50 0.002 and 0.004 lM, respectively). At 72-h post-removal of 0.1 lM vincristine (Figs. 4G and H) , there was a significant reduction in both neuronal (31%) and non-neuronal (34%) cell counts. A dose-dependent reduction in both neurite and non-neuronal process areas was also observed 72-h postvincristine removal (IC 50 0.024 or 0.036 lM, respectively). Significant differences in compound effects on cell counts and process areas were observed at both 24-and 72-h post-drug removal (P values .0066) indicating that neurites or nonneuronal processes were more sensitive to vincristine. Although neuronal cell counts were not affected at 24 h, a reduction was observed 72-h post-drug removal suggesting initial effects in neuronal cell bodies were sublethal and may have progressed. Effects on neurite area and non-neuronal process area 72 h (after vincristine removal) were decreased compared with what was observed at 24 h, suggesting recovery of vincristine-induced effects. Figure 5 shows the responses of the DRG-culture to eribulin. Eribulin had selective effects on non-neuronal cell counts at both 24-and 72-h time point. There were no statistically significant changes in the neuronal cell counts at concentrations up to 1 mM, but dose-dependent reductions in non-neuronal cell counts (IC 50 0.78 and 0.15 lM, respectively) were observed at 24 ( Figure 5D ) and 72 h ( Figure 5H ). In contrast, eribulin induced a prominent, dose-dependent reduction in both neuronal and non-neuronal process areas with IC 50 0.026 and 0.033 lM after 24-h drug exposure (Figs. 5C and D) or with IC 50 0.016 and 0.014 lM at 72-h postdrug removal (Figs. 5G and H) , respectively. Significant differences were observed between the effects on cell counts and effects on neurite or process areas at each time point (P values < .0001) indicating that neurites or non-neuronal processes were more sensitive to the effects of eribulin than neuronal or non-neuronal cell bodies. The reduction in neurite area, non-neuronal cell counts and non-neuronal process areas 72-h post-drug removal was significantly increased compared with 24 h suggesting effects of eribulin were progressive and not reversible.
Eribulin
Paclitaxel
Effects of paclitaxel on DRG cultures are provided in Figure 6 . After 24-h treatment, paclitaxel at concentrations of 10 and 30 lM caused a statistically significant decrease (by 24% and 32%, respectively) in the non-neuronal cell process area ( Figure  6D ). At 72-h post-drug removal, paclitaxel caused a dosedependent reduction in neurite and non-neuronal process areas (IC 50 9.45 and 18.53 lM, respectively) and a statistically significant reduction (by 24%) in non-neuronal cell counts at 30 lM (Figs. 6G and H ). Significant differences in effects on the neuronal cell count and neurite area at 72 h or the non-neuronal cell and probed with anti-tuj-1 (MO15013 1:50, plus anti-GAPDH 1:100) or anti-vimentin (AB8069 1:1000, plus anti-GAPDH 1:100); Tuj-1, Vimentin and GAPDH were detected at 55, 58 and 42 kDa, respectively. B, Tuj-1 and vimentin expression normalized to GAPDH (mean 6 SEM, n ¼ 3-4). C, A representative field of four channels; merged images taken with 20Â objective from a vehicle control well. Neurons, neurites and non-neuronal cells, processes are stained positive for Tuj-1 (in red) and Vimentin (in green), respectively; Closed arrows point to the neuronal cell body (Tuj-1 in red) and nuclei (NeuN in white); Open arrows point to running of a single thread of neurite and process in close contact; Stars denote cells with a unique morphology distinctive from Schwann cells.
count and process areas at both 24 and 72 h were observed (P values < 0.0001), indicating that neurites or non-neuronal processes were more vulnerable than neuronal or non-neuronal cell bodies to paclitaxel. As with eribulin, effects of paclitaxel were progressive and not reversible. After 24-h drug exposure and at 72-h post-drug removal, paclitaxel also caused an increase in the size of neuronal cell bodies and adjacent neurites at concentrations ! 0.1 lM and ! 1 lM, respectively (Figs. 6B, 6F and 10A). These changes occurred without any notable loss of neurites.
Cisplatin
Effects of cisplatin on DRG cells are shown in Figure 7 . After 24-h exposure, cisplatin caused a statistically significant reduction in the neuronal cell count by 22% at 100 lM or in the neuronal process area by 33% at 30 lM and by 45% at 100 lM ( Figure 7C ). Cisplatin did not cause a significant decrease in non-neuronal cell counts at concentrations up to 100 lM, but there was a statistically significant, dose-dependent reduction in the nonneuronal process area after 24-h drug exposure ( Figure 7D ; IC 50 37.73 lM). Seventy-two-hour post-cisplatin removal, a reduction in neuronal cell counts ( Figure 7G ; IC 50 28.85), non-neuronal cell counts ( Figure 7H ; IC 50 61.62 lM), neurite area ( Figure 7G ; IC 50 8.03 lM) and non-neuronal process area ( Figure 7H ; IC 50 10.98 lM) was observed. Similar to paclitaxel, a significant difference in effects on neuronal cell counts compared with effects on neurite area was observed at 72-h post-drug removal ( Figure  7G ; P < .0001), but not at 24-h drug exposure ( Figure 7C ; P ¼ .1654). However, significant differences between effects on non-neuronal cell counts compared with effects on non-neuronal processes were observed at both time points (Figs. 7D and H; P values < .0001). These findings provide evidence of differential sensitivity of cell processes (neuronal or non-neuronal) to cisplatin. In addition, changes observed were more extensive 72-h post-drug removal compared with those observed at 24 h implying effects of cisplatin were progressive, persistent and not reversible. Fragmentation of processes was also observed at concentrations ! 10 lM at 24-h drug exposure and 72 h after cisplatin removal as shown in Figs. 7B, 7F and 10B. Bortezomib Figure 8 shows the response of DRG cells to bortezomib. After 24-h exposure, a statistically significant reduction by 27% in neurite area was apparent at the 1.0 lM concentration and a dosedependent reduction in non-neuronal process area (IC 50 0.72 lM) was observed (Figs. 8C and D ). There were no significant effects on either neuronal or non-neuronal cell counts at 24 h (Figs. 8C and D). At 72-h post-drug removal (Figs. 8G and H), dosedependent reductions in neuronal and non-neuronal cell counts (IC 50 0.12 and 0.08 lM, respectively), as well as neurite and nonneuronal process areas (IC 50 0.03 lM for both) were observed. Significant differences were observed between compound effects on cell counts and process areas for neuronal and non-neuronal cells at each time point (P values .0087). In addition, reductions observed in neuronal cell counts, neurite area, non-neuronal cell counts and non-neuronal process area 72 h after drug removal were more profound compared with 24 h suggesting effects of bortezomib were also progressive and not reversible. Fragmentation of neurites was observed after 24-h exposure to 1.0 lM bortezomib and 72 h after drug removal (Figs. 8B and F) .
Thalidomide, Gefitinib and Hydroxyurea Figure 9 shows the dose-response of DRG cell cultures to treatment with thalidomide, gefitinib and hydroxyurea. No statistically significant effects were observed at any concentration tested with these drugs. However, it is worth noting that there was a reduction in neuronal and non-neuronal cell count and process area at 10 lM gefitinib 72-h post-drug removal, although not statistically significant. The measurement for neuronal and non-neuronal cell counts was reduced from 423 6 151 (mean 6 SEM) to 316 6 108 (by 25%) and from 3432 6 865 to 2555 6 348 (by 16%), respectively. Reduction in the process area (mm 2 ) of neurites and processes was 1.58 6 0.12 to 1.21 6 0.19
(by 23%) and 1.47 6 0.04 to 0.93 6 0.28 (by 37%), respectively.
Morphologic Changes Observed
After 24-h exposure to concentrations ! 0.1 lM paclitaxel, enlargement of neuronal cell bodies was observed ( Figure 10A ). Swelling was deemed a reversible change for concentrations <1.0 lM because at 72-h post-paclitaxel removal, no statistically significant swelling was observed. Cisplatin caused a dosedependent fragmentation of neurites ( Figure 10B) . A significant increase in neurite fragmentation was observed in cells treated with concentrations ! 10 lM cisplatin at 24-h exposure. A more profound increase was noted 72 h after cisplatin was removed. 
DISCUSSION
Our goal was to establish a cell-based assay to screen compounds for potential risk of CIPN at early stages of drug development. Clinically, CIPN is manifested predominately with loss of sensory function (Argyriou et al., 2014; Hershman et al., 2014; Miltenburg and Boogerd, 2014) . The reduction in the amplitude of sensory nerve action potentials and the 'dying back' degeneration of nerve terminals of sensory neurons residing in DRGs are hallmarks of the neurophysiological and histopathological basis of CIPN (Argyriou et al., 2014) . The primary rat DRG cell culture model is a heterogeneous system containing multiple cell types residing in a dorsal root ganglion, and therefore represents a more physiologically relevant model than those using highly purified neuronal cell lines or human iPSC-derived neurons. Indeed, non-neuronal supporting cells in DRGs play an important role in ensuring the health, functionality, and regeneration of sensory neurons (Ard et al., 1987; Grothe and Unsicker, 1987) . Although DRG neuronal cells are the primary targets of most CIPN agents, non-neuronal supporting cells may modulate the response of sensory neurons to, or be the direct target of, CIPN agents (Carozzi et al., 2015b; Peters et al., 2007) . Hence, the in vitro system presented herein has the potential to support investigations of more complex multicellular mechanisms of CIPN.
In order to conduct a cell type-specific analysis of morphological responses to CIPN agents, we evaluated more than 10 biomarkers commonly used to label neurons and non-neuronal cells. Based on criteria of high-level specificity and signal intensity, we selected NeuN and Tuj-1 (b-III tubulin) as the markers for neuronal cell nuclei, and cell bodies and neurites, respectively. Vimentin was chosen as the marker for non-neuronal cell bodies and processes, particularly for Schwann cells, judging by nuclear expression of SOX2 and characteristic morphologic features, such as small, spindle-shaped nuclei with little cytoplasm and bipolar cell processes in close contact with neurites.
Sural nerve biopsy and postmortem examinations of CIPN are rarely performed . As a result, most of the available data regarding the pathological changes associated with CIPN have been obtained in rodent experimental models (Cavaletti et al., 2008) . In these models, 'dying back' degeneration of sensory nerves residing in DRGs that starts at the distal end and progresses retrograde to their cell bodies is a pathological hallmark of CIPN (Carozzi et al., 2015b; Cheng et al., 2015; Han and Smith, 2013; Hoke and Ray, 2014; Miltenburg and Boogerd, 2014) . A major goal for an in vitro model is to reproduce the morphological features of neuronal damage and show that neurites are more susceptible than neuronal cell bodies to agents that cause CIPN (Marmiroli et al., 2012) . Therefore, the focus of our image analysis was to obtain sets of parameters that measure cell loss and quantify morphologic changes in neurites or processes of neuronal or non-neuronal cells. Except for thalidomide, all CIPN agents tested exhibited a characteristic morphological change in that they caused a greater loss of neurites or processes than counts of neuronal or non-neuronal cell bodies, a feature characteristic of the 'dying back' degeneration of sensory nerves observed histologically both in biopsies from patients with CIPN and in animal models (Marmiroli et al., 2012; McLeod and Penny, 1969) .
CIPN is a major adverse effect of thalidomide therapy, manifested predominately by sensory axon degeneration as the pathological alteration (Cundari and Cavaletti, 2009 ). Thalidomide did not cause any significant changes in cultured DRG cells, at concentrations up to 300 lM, which is $33-fold the clinical Cmax (Scheffler et al., 1999) . The aqueous solubility of thalidomide is reported as 2.55 mg/ml ($10 mM, see 'http:// www.drugbank.ca/drugs/DB01041'), and no precipitates were observed at 300 lM in culture media. The lack of measurable effects of thalidomide in this culture system are likely due to the fact that thalidomide-induced peripheral neuropathy is mediated by its antiangiogenic effects (Kirchmair et al., 2007) . Our findings are therefore consistent with this indirect mechanism of action and consistent with results of a previous in vitro study FIG. 8 . Effects of bortezomib on cultured DRG cells. A, B, E and F, Merged images taken after 24-h drug exposure (A and B) or 72-h post-drug removal (E and F); Scale bar, 40 lm. Concentration-dependent effects, shown as percent of vehicle control, on cell count or process area for neuronal (C and G) or non-neuronal (D and H) cells after 24-h drug exposure (C and D) or 72-h post-drug removal (G and H), respectively. Mean 6 SEM; n ¼ 6 replicate experiments, *P < 0.05 at drug concentration compared with respective vehicle controls; P values in the lower left of each graph indicate the significance level in changes between cell count and neurite or process area as determined by the 2-way ANOVA. Fitting to neuronal count at 24 h was not converged. (Aronson et al., 1984) . Notably, attempts to establish a thalidomide PN rodent model has not been successful.
Comparing the IC 50 values for neuronal cell endpoints to the IC 50 for non-neuronal cell endpoints may be useful in interpretation of cell-population susceptibility. For example, bortezomib treatment resulted in a more profound decrease in nonneuronal cell process areas compared with neuronal cells or neurite area during the 24-h drug exposure period. These results are consistent with findings from an in vivo study that showed bortezomib induced pathological changes predominantly in the non-neuronal, supporting cells (Cavaletti et al., 2007) .
Comparing the IC 50 values for decreased cell count or neurite/process areas at 24-h exposure to the IC 50 values at 72-h post-drug removal may inform whether there is potential for recovery. The effects of vincristine were partially reversible after drug removal, consistent with clinical findings (Postma et al., 1993) . However, for the other CIPN-inducing agents, progressive deterioration in morphological alterations 72 h after drug removal was observed. This observation relates CIPN symptoms that get progressively worse for some agents and persist long after completion of treatment (Fehrenbacher, 2015; Hershman et al., 2014) .
The difference (margin) between IC 50 values and in vivo maximal serum exposure (Cmax) may inform the level of risk for CIPN. A narrower margin between IC 50 and Cmax may flag a higher potential to induce CIPN. For example, the lowest margin calculated as IC 50 divided by Cmax was 0.1 for bortezomib, 0.6 for cisplatin, 0.01 for eribulin, 2.0 for paclitaxel and 0.3 for vincristine, but was ! 28 for gefitinib and > 4 for hydroxyurea.
Loss of neurites or processes may be used as a predictor of CIPN risk, but for some drugs, morphological change may be an earlier indicator and also provide clues to underlying mechanisms. For example, dose-and time-dependent fragmentation of neurites and enlarged neuronal cell bodies were observed with cisplatin and paclitaxel, respectively prior to loss of cells or neurites. Cisplatin is known to activate an apoptotic pathway and breakdown cytoskeletal proteins both in vivo and in vitro (Gill and Windebank, 1998; Park et al., 2000; Ta et al., 2006) , whereas paclitaxel enhances the polymerization of tubulin, stabilizing microtubules and leading to accumulative deposition of non-functional tubulins in neurons (Horwitz, 1994) . The enlarged neuronal cell bodies appeared to reverse following drug removal, indicating there may be a target time-frame for mitigation strategies.
Many groups are investigating various hypotheses about the molecular mechanisms underlying CIPN and are reviewed in depth elsewhere (Boyette-Davis et al., 2015; Carozzi et al., 2015a) . Various cell types are targets for chemotherapy-mediated toxicity with a broad range of mechanisms including DNA damage, alterations in cellular system repairs, mitochondrial changes, increased intracellular reactive oxygen species, alterations in ion channels, and glutamate signaling. The list of drugs that cause CIPN are as varied as the proposed mechanisms and include vinca alkaloids (vincristine), cisplatin, paclitaxel, etoposides and thalidomide. The most frequently investigated mechanism for the pathogenesis of CIPN involves damage to glial and neuronal mitochondria and related oxidative stressmediated damage to the cells. Research on mechanisms of CIPN have also focused on the effects of drugs on neuronal ion channel responses and activation regulation of intracellular signaling pathways. Agents such as bortezomib and cisplatin can also damage lysosomes and endoplasmic reticulum, and inhibit axonal transport in neurons and Schwann cells in culture (Santin et al., 2012; Shin et al., 2010) . A review of the genes and SNPs that have been implicated as potentially predictive for CIPN has also been published, although it is unclear how many of these actually contribute mechanistically to CIPN (Cavaletti et al., 2011) .
We have characterized an in vitro DRG model that can be used to quantify and qualify the morphologic effects consistent with CIPN. Comparative evaluation of neurite area and neuronal cell/body counts allowed evaluation of neurite selective CIPNspecific risk versus overt cytotoxicity. Drug effects on nonneuronal cells, ie, Schwann cells, may also be evaluated for contribution to CIPN and these effects can be differentiated from effects on neuronal cells. Finally, drug-specific changes in subcellular structures can be used to further evaluate mechanisms of CIPN. The DRG mixed cell culture system presented here can be aptly used to discover treatments to relieve this painful condition.
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